A Luciferase Immunosorbent Assay Based on Attachment Glycoprotein for the Rapid and Easy Detection of Nipah Virus IgG Antibodies

Xinyue Li, Yuting Fang, Xinyi Huang, Yongkun Zhao, Chengsong WanMicroorganisms 2024 · DOI

TL;DR

Researchers have developed a novel, rapid, and highly sensitive luciferase immunosorbent assay (LISA) for detecting Nipah virus (NiV) IgG antibodies. This new assay utilizes a specific fragment of the NiV attachment glycoprotein (G) fused to a nanoluciferase reporter, offering a significant improvement in sensitivity and ease of use compared to traditional methods like ELISA, paving the way for better NiV monitoring and outbreak response.

What Problem Does This Paper Address?

Nipah virus (NiV) is a highly pathogenic zoonotic virus with a broad host range and pandemic potential, posing a significant threat to public health. Current diagnostic methods for NiV infection, such as virus isolation, require specialized high-containment laboratories (BSL-4), while molecular diagnostics can be limited by viral RNA degradation. Serological tests offer a more accessible and rapid alternative for large-scale screening and epidemiological studies, but existing methods like indirect ELISA have limitations. Specifically, indirect ELISAs often require species-specific secondary antibodies, complicating their application across different animal hosts. Furthermore, some assays require virus-infected cellular antigens, which can be difficult to obtain and handle. There is a clear need for a sensitive, specific, rapid, and broadly applicable diagnostic tool for NiV IgG antibodies that can be used in diverse settings.

Methods

The core of this research is the development of a Luciferase Immunosorbent Assay (LISA). The key innovation lies in creating a fusion protein consisting of nanoluciferase (NanoLuc), a highly bright and efficient bioluminescent reporter, and a specific fragment of the NiV attachment glycoprotein (G).

Here's a breakdown of the methodology:

  • Antigen Design and Expression: Researchers identified the NiV G protein's head domain (amino acids 176–602) as a promising target. They engineered five recombinant plasmids to express different fragments of the G protein, including the full-length protein and truncated versions of the head domain, each fused with a 6xHis tag for detection. These plasmids were transfected into HEK 293T cells for expression of the luciferase fusion proteins.
  • LISA Protocol: The assay involves coating microtiter plates with the NiV G protein fragment. Patient or animal serum samples are then added to bind to any specific NiV IgG antibodies present. After washing, the NanoLuc-fused G protein is added, which binds to the captured antibodies. Finally, a luciferase substrate is added, producing a luminescent signal proportional to the amount of NiV IgG present.
  • ELISA Comparison: A standard indirect ELISA was also performed using a different NiV G protein fragment (aa 71-602) for comparative sensitivity analysis.
  • Specificity and Cross-Reactivity Testing: The developed LISA was tested against sera from animals infected with other viruses (Ebola, Rift Valley fever, Crimean-Congo hemorrhagic fever, West Nile) and human patients infected with Chikungunya, Dengue, and Hepatitis C viruses to assess its specificity.
  • Sensitivity Analysis: Serial dilutions of positive serum samples were used to determine the lower limit of detection for both the LISA and the indirect ELISA.

Datasets

The study utilized serum samples from the following sources:

  • Mouse Sera: Samples from mice immunized with NiV G-protein (n=9) and negative control mice (n=9) were prepared in the lab.
  • Horse Sera: NiV-positive horse sera, along with sera positive for Ebola virus (EBOV), Rift Valley fever virus (RVFV), Crimean–Congo hemorrhagic fever virus (CCHFV), and West Nile virus (WNV), were provided by the Changchun Veterinary Research Institute.
  • Human Sera: Sera from patients infected with Chikungunya virus (CHIKV) and Dengue virus (DENV) were provided by the Guangdong Center for Disease Control and Prevention. Normal human sera and Hepatitis C virus (HCV) sera were also used.

No new benchmark datasets were introduced; rather, existing serum samples were used for validation.

Key Insights and Ideas

  • The NiV G protein head domain is a critical target: The research strongly suggests that the head domain of the NiV G protein (amino acids 176–602) contains crucial epitopes for antibody binding and is the optimal region for developing serological assays.
  • NanoLuc amplifies the signal: The use of nanoluciferase, known for its high luminescence output, significantly boosts the assay's sensitivity, allowing for the detection of even low levels of antibodies.
  • LISA offers superior sensitivity: The developed LISA demonstrated at least a fourfold increase in sensitivity compared to a traditional indirect ELISA, meaning it can detect antibodies at much lower concentrations.
  • Broad applicability across species: A significant advantage of this LISA is its ability to detect NiV IgG in both mouse and horse serum without the need for species-specific secondary antibodies, which is a major limitation of conventional ELISAs.
  • Structural integrity matters: The study highlights that maintaining the structural integrity of the G protein head domain (G-C1 fragment) is crucial for optimal detection, as truncating it further (G-C2, G-C3, G-C4) led to reduced efficacy.

Key Results

  • Optimal Antigen Fragment: The G-Full (full-length G protein) and G-C1 (G protein head domain, aa 176–602) fragments showed the best performance in detecting NiV IgG antibodies in mouse serum, with a 100% detection rate.
  • Sensitivity Improvement: The LISA was approximately four to eight times more sensitive than indirect ELISA, with a lower limit of detection for G-C1 at dilutions up to 1:256,000, compared to 1:32,000 for ELISA.
  • Specificity: The G-C1-LISA demonstrated good specificity, correctly identifying NiV-positive horse sera and showing no cross-reactivity with sera from animals infected with other viruses (EBOV, RVFV, CCHFV, WNV). It also did not detect specific IgG in human patients infected with CHIKV, DENV, and HCV.
  • Cross-Species Testing: The assay successfully detected NiV IgG in both mouse and horse serum, indicating its potential for broad application in monitoring NiV in various hosts.

Limitations and Future Work

  • Human Sample Validation: While the assay showed good specificity against some human viral infections, the authors acknowledge that more human sera from various infection statuses would be required to fully validate and optimize the LISA for human diagnostics.
  • Accessibility of Positive Samples: The paper notes that obtaining NiV-positive samples, especially from natural hosts like bats, can be challenging, which is a general hurdle for developing and validating NiV diagnostics.
  • Optimization for Specific Hosts: Although the LISA demonstrated cross-species capability, further optimization might be needed for specific host species, particularly for less common hosts or those with unique immune responses.

The authors suggest that this rapid, simple, and sensitive NiV LISA using the G protein head domain provides a valuable resource for NiV monitoring and could be applied for large-scale screening in natural foci to assess epidemic risk.

Summary updated

Abstract

Nipah virus (NiV) is a virulent zoonotic disease whose natural host is the fruit bat (<i>Pteropus medius</i>), which can coexist with and transmit the virus. Due to its high pathogenicity, wide host range, and pandemic potential, establishing a sensitive, specific, and rapid diagnostic method for NiV is key to preventing and controlling its spread and any outbreaks. Here, we established a luciferase immunosorbent assay (LISA) based on the NiV attachment glycoprotein (G) to detect NiV-specific immunoglobulin G by expressing a fusion protein of nanoluciferase (NanoLuc) and the target antigen. Sensitivity analysis was performed and compared to an indirect enzyme-linked immunosorbent assay (ELISA), and specificity and cross-reactivity assessments were performed using NiV-positive horse serum and Ebola virus-, Crimean-Congo hemorrhagic fever virus-, and West Nile virus-positive horse sera. The optimal structural domain for NiV detection was located within amino acids 176-602 of the NiV G protein head domain. Moreover, the LISA showed at least fourfold more sensitivity than the indirect ELISA, and the cross-reactivity results suggested that the LISA had good specificity and was capable of detecting NiV-specific immunoglobulin G in both mouse and horse serum. In conclusion, the establishment of a rapid, simple NiV LISA using the G protein head domain provides a resource for NiV monitoring.
BibTeX
@inproceedings{li2024luciferase,
  author = {Xinyue Li and Yuting Fang and Xinyi Huang and Yongkun Zhao and Chengsong Wan},
  title = {{A Luciferase Immunosorbent Assay Based on Attachment Glycoprotein for the Rapid and Easy Detection of Nipah Virus IgG Antibodies}},
  booktitle = {Microorganisms},
  year = {2024},
  doi = {10.3390/microorganisms12050983},
}
Figure